Dakota Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.26M | Buy |
2,829
+206
| +8% | +$96.1K | 0.03% | 361 |
|
|
2025
Q4 | $1.19M | Buy |
2,623
+43
| +2% | +$18.5K | 0.02% | 370 |
|
|
2025
Q3 | $1.01M | Sell |
2,580
-430
| -14% | -$180K | 0.02% | 352 |
|
|
2025
Q2 | $1.34M | Sell |
3,010
-7,137
| -70% | -$3.29M | 0.03% | 338 |
|
|
2025
Q1 | $4.92M | Buy |
10,147
+2,739
| +37% | +$1.28M | 0.12% | 156 |
|
|
2024
Q4 | $2.98M | Sell |
7,408
-26,985
| -78% | -$12.5M | 0.07% | 214 |
|
|
2024
Q3 | $16M | Buy |
34,393
+4,042
| +13% | +$1.94M | 0.36% | 57 |
|
|
2024
Q2 | $14.2M | Sell |
30,351
-2,031
| -6% | -$882K | 0.33% | 59 |
|
|
2024
Q1 | $13.5M | Buy |
32,382
+9,240
| +40% | +$3.91M | 0.34% | 67 |
|
|
2023
Q4 | $9.42M | Buy |
23,142
+20,427
| +752% | +$7.55M | 0.37% | 80 |
|
|
2023
Q3 | $944K | Buy |
2,715
+802
| +42% | +$280K | 0.04% | 293 |
|
|
2023
Q2 | $673K | Buy |
1,913
+319
| +20% | +$107K | 0.03% | 326 |
|
|
2023
Q1 | $502K | Sell |
1,594
-247
| -13% | -$74.1K | 0.03% | 363 |
|
|
2022
Q4 | $532K | Sell |
1,841
-475
| -21% | -$145K | 0.04% | 345 |
|
|
2022
Q3 | $670K | Buy |
2,316
+174
| +8% | +$50.1K | 0.05% | 287 |
|
|
2022
Q2 | $604K | Sell |
2,142
-139
| -6% | -$37.2K | 0.06% | 252 |
|
|
2022
Q1 | $595K | Buy |
2,281
+281
| +14% | +$66.7K | 0.05% | 260 |
|
|
2021
Q4 | $439K | Hold |
2,000
| – | – | 0.05% | 259 |
|
|
2021
Q3 | $363K | Hold |
2,000
| – | – | 0.04% | 261 |
|
|
2021
Q2 | $403K | Hold |
2,000
| – | – | 0.05% | 251 |
|
|
2021
Q1 | $430K | Sell |
2,000
-23
| -1% | -$5.05K | 0.06% | 228 |
|
|
2020
Q4 | $478K | Buy |
2,023
+8
| +0.4% | +$1.84K | 0.06% | 214 |
|
|
2020
Q3 | $548K | Sell |
2,015
-9,531
| -83% | -$2.63M | 0.09% | 167 |
|
|
2020
Q2 | $3.35M | Buy |
11,546
+9,546
| +477% | +$2.59M | 0.57% | 51 |
|
|
2020
Q1 | $476K | Hold |
2,000
| – | – | 0.1% | 157 |
|
|
2019
Q4 | $438K | Hold |
2,000
| – | – | 0.07% | 208 |
|
|
2019
Q3 | $339K | Hold |
2,000
| – | – | 0.06% | 223 |
|
|
2019
Q2 | $367K | Hold |
2,000
| – | – | 0.07% | 202 |
|
|
2019
Q1 | $368K | Hold |
2,000
| – | – | 0.07% | 216 |
|
|
2018
Q4 | $385K | Hold |
2,000
| – | – | 0.09% | 184 |
|
|
2018
Q3 | $385K | Hold |
2,000
| – | – | 0.09% | 181 |
|
|
2018
Q2 | $340K | Hold |
2,000
| – | – | 0.09% | 158 |
|
|
2018
Q1 | $326K | Hold |
2,000
| – | – | 0.17% | 61 |
|
|
2017
Q4 | $300K | Hold |
2,000
| – | – | 0.16% | 62 |
|
|
2017
Q3 | $304K | Hold |
2,000
| – | – | 0.16% | 53 |
|
|
2017
Q2 | $258K | Hold |
2,000
| – | – | 0.14% | 55 |
|
|
2017
Q1 | $219K | Buy |
+2,000
| New | +$176K | 0.13% | 60 |
|
|
2016
Q1 | – | Sell |
-2,000
| Closed | -$252K | – | 54 |
|
|
2015
Q4 | $252K | Hold |
2,000
| – | – | 0.17% | 46 |
|
|
2015
Q3 | $208K | Hold |
2,000
| – | – | 0.14% | 47 |
|
|
2015
Q2 | $247K | Hold |
2,000
| – | – | 0.15% | 49 |
|
|
2015
Q1 | $236K | Hold |
2,000
| – | – | 0.14% | 52 |
|
|
2014
Q4 | $238K | Buy |
+2,000
| New | +$225K | 0.15% | 51 |
|
Other funds holding VRTX
VCM
VPM
Dakota Wealth Management's VRTX Position: Q1 2026 in Review
Dakota Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 7.9% in Q1 2026, buying an estimated $96.1K and bringing the position to 2,829 shares worth $1.26M. The position accounts for 0.03% of the portfolio, ranked #361.
Dakota Wealth Management first reported a position in VRTX in Q4 2014 and has held it in 42 quarters since. The position peaked at $16M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Dakota Wealth Management held 2,829 shares of Vertex Pharmaceuticals worth $1.26M as of Q1 2026.
- Dakota Wealth Management bought 206 Vertex Pharmaceuticals shares in Q1 2026, an estimated $96.1K.
- Vertex Pharmaceuticals made up 0.03% of Dakota Wealth Management's portfolio in Q1 2026, its #361 holding.
- Dakota Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 42 quarters since.
- Dakota Wealth Management's Vertex Pharmaceuticals position peaked at $16M in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Dakota Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.